Technology area: Biotechnology & Pharmaceuticals
69 pending office actions • 30 art units • 60 examiners • 0 of 69 (0%) have an AI response strategy ready • 42 patents granted in the last 365 days
Janssen Pharmaceuticals Inc. has 68 pending office actions in Biotechnology & Pharmaceuticals. The docket covers 61 distinct examiners and 31 distinct art units, reflecting broad examiner distribution with recurring activity in several technical classifications.
SANG, HONG is the busiest examiner, with 3 pending matters. The concentration is limited against the full docket, so prosecution oversight should focus on consistent portfolio processes, supported by art-unit analysis and examiner-specific response planning.
Based on the USPTO statutory response window for each pending office action. 23 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 23 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 7 (10%) |
| §103 only | 13 (19%) |
| §112 only | 6 (9%) |
| Double-patenting only | 8 (12%) |
| Double-patenting + other | 16 (23%) |
| Multi-statute (no §101) | 16 (23%) |
| No statute on record | 2 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANG, HONG | 3 | 54.9% | +62.8% |
| SULLIVAN, DENNIS JOHN | 3 | 57.6% | +48.0% |
| POPA, ILEANA | 2 | 21.7% | +15.7% |
| HOLTZMAN, KATHERINE ANN | 2 | 64.8% | +59.4% |
| MARVICH, MARIA | 2 | 55.0% | +28.0% |
| HUYNH, PHUONG N | 2 | 65.8% | +53.6% |
| GUSTILO, ESTELLA M | 2 | 53.6% | +34.5% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
| OGLES, MATTHEW ERIC | 1 | 50.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 164d overdue |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 88d overdue |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | FORD, VANESSA L | 17d overdue |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 20d |
| 18037204 | TREATMENT OR PREVENTION OF HIV INFECTION | SWIFT, CANDICE LEE | 26d |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 34d |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 88d overdue |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | SULLIVAN, DENNIS JOHN | 70d overdue |
| 17806581 | RECOMBINANT VIRUS REPLICON SYSTEMS AND USES THEREOF | MARVICH, MARIA | 43d overdue |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 10d overdue |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 4d overdue |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 13d |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 54d |
| Art Unit | Apps |
|---|---|
| 1646 | 10 |
| 1643 | 6 |
| 3783 | 4 |
| 1644 | 4 |
| 1647 | 4 |
| 1642 | 4 |
| 1634 | 3 |
| 1641 | 3 |
| 1674 | 3 |
| 3791 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19658174 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | Other | Non-Final OA | — | Pending | Apr 24, 2026 |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | 1646 | §102§103§112 | Final Rejection | — | Pending | Dec 12, 2025 |
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | IVICH, FERNANDO NMN | 1678 | §101§102§103§112Other | Non-Final OA | — | Pending | Jul 25, 2025 |
| 19107952 | PATIENT TRAINER MIRROR | OGLES, MATTHEW ERIC | 3791 | §101§103§112 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18939761 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF | ROSENTHAL, ANDREW S | 1613 | §103DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18846889 | SHELL FOR SMALL VIAL TO FIT INTO INJECTOR OR CAP REMOVER | WHITROCK, ZACHARIAH KIRBY | 3783 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18771839 | Combination Therapies with Anti-CD38 Antibodies | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18765663 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | PETRASH, HILARY ANN | 1644 | §102§112DP | Final Rejection | — | Pending | Jul 08, 2024 |
| 18721021 | Urinary Placement Catheter for Intravesical Devices | MENDEZ, MANUEL A | 3783 | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18711131 | Method of Treating Geographic Atrophy with a Gene Therapy Vector Expressing Soluble CD59 | POPA, ILEANA | 1633 | §102§103 | Non-Final OA | — | Pending | May 17, 2024 |
| 18703264 | BIOSYNTHETIC MONOVALENT BINDING MOLECULES WITH ENHANCED EFFECTOR FUNCTIONS | HOLTZMAN, KATHERINE ANN | 1646 | §103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18639233 | METHODS FOR TREATING MULTIPLE MYELOMA | FAUST, AMBER KATHLEEN | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18639242 | METHODS FOR TREATING MULTIPLE MYELOMA | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18613945 | USE OF APPROVED BISPECIFIC EGFR AND MET SPECIFIC ANTIBODY DRUG PRODUCT TO TREAT NON-SMALL CELL LUNG CANCER | LANDSMAN, ROBERT S | 1647 | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18691254 | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | WEIDNER, ADAM M | 1675 | §112DP | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18592234 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 1644 | §101§102§103§112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18588224 | COMPOSITIONS COMPRISING A BISPECIFIC GPRC5D/CD3 ANTIBODY | JOHNSON, TIRONE DEREK | 1675 | §101§103 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18583364 | Neoantigens Expressed In Ovarian Cancer And Their Uses | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18444595 | Anti-IL-23 Antibodies | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18439951 | METHODS FOR TREATING MULTIPLE MYELOMA | BUNNER, BRIDGET E | 1647 | DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18545113 | ONCOLYTIC VIRUS AND USES THEREOF | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | NATARAJAN, MEERA | 1643 | §112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | GRABER, JAMES J | 1631 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18499720 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | HUYNH, PHUONG N | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18555924 | MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS | HUYNH, PHUONG N | 1641 | §102§103§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | XIAO, YAN | 1642 | DP | Non-Final OA | 28d | Pending | Sep 26, 2023 |
| 18549795 | BIOENGINEERED IMMUNOMODULATORY FUSION PROTEIN COMPOSITIONS | KAUFMAN, CLAIRE M | 1674 | §102§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18344973 | MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | §103 | Final Rejection | 21d | Pending | Jun 30, 2023 |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 1642 | §103Other | Non-Final OA | 54d | Pending | Jun 29, 2023 |
| 18210885 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | BRISTOL, LYNN ANNE | 1643 | §103Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | SAOUD, CHRISTINE J | 1645 | DP | Final Rejection | 46d | Pending | Jun 01, 2023 |
| 18199007 | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody | LOCKARD, JON MCCLELLAND | 1647 | §112 | Final Rejection | 6d | Pending | May 18, 2023 |
| 18249807 | PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | SULLIVAN, DENNIS JOHN | 1642 | §103DP | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | 70d overdue | Pending | Apr 13, 2023 |
| 18180693 | Palm Activated Drug Delivery Device | SCHMIDT, EMILY LOUISE | 3783 | DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 1646 | DP | Final Rejection | 10d overdue | Pending | Feb 27, 2023 |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | FORD, VANESSA L | 1674 | §102§103 | Final Rejection | 17d overdue | Pending | Feb 09, 2023 |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | REDDIG, PETER J | 1646 | §103DP | Final Rejection | 28d | Pending | Feb 07, 2023 |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | BARRERA, IMMACULADA | 1671 | DP | Final Rejection | 74d overdue | Pending | Dec 13, 2022 |
| 18009135 | CONTROLLED RELEASE OF SELF-EMBEDDING PARTICLES FOR LOCALIZED DRUG DELIVERY | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | — | Pending | Dec 08, 2022 |
| 18053904 | STABLE FORMULATIONS COMPRISING A BISPECIFIC BCMA/CD3 ANTIBODY | DUNN, LINDSAY MICHELLE | 1600 | §102§103 | Non-Final OA | — | Pending | Nov 09, 2022 |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | 88d overdue | Pending | Nov 02, 2022 |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 1796 | §101§103 | Final Rejection | 20d | Pending | Oct 11, 2022 |
| 17860244 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112 | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103§112Other | Non-Final OA | 147d overdue | Pending | May 26, 2022 |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | 49d overdue | Pending | May 25, 2022 |
| 17767263 | MATERIALS AND METHODS FOR MASS SPECTROMETRIC PROTEIN ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Non-Final OA | 9d | Pending | Apr 07, 2022 |
| 17615949 | ANTI-TNF ANTIBODY COMPOSITIONS, AND METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS | DAHLE, CHUN WU | 1641 | DP | Final Rejection | — | Pending | Dec 02, 2021 |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 1646 | §103Other | Non-Final OA | 13d | Pending | Apr 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJanssen Pharmaceuticals Inc. has 69 pending office actions as of October 2026, spread across 30 art units and 60 examiners.
Hong Sang has the most, with 3 of Janssen Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
